Download PDF
Fortschr Neurol Psychiatr 2005; 73(5): 268-285
DOI: 10.1055/s-2004-830193
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Therapie von Schmerzen bei MS - eine Übersicht mit evidenzbasierten Therapieempfehlungen

Therapy of Pain Syndromes in Multiple Sclerosis - An Overview with Evidence-Based RecommendationsW.  Pöllmann1 , W.  Feneberg1 , A.  Steinbrecher2 , M.  R.  Haupts3 , T.  Henze4
  • 1Marianne Strauß-Klinik, Berg
  • 2Neurologische Universitätsklinik, Regensburg
  • 3Neurologische Universitätsklinik, Bochum
  • 4Klinik am Regenbogen, Nittenau
Further Information

Publication History

Publication Date:
02 February 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Schmerzen sind ein häufiges Problem für Multiple Sklerose-(MS)-Patienten, das oft gezielt erfragt werden muss. Sie lassen sich unter diagnostischen und therapeutischen Gesichtspunkten in 4 Kategorien einteilen: 1. Schmerzen als direkte Folge einer MS: Schmerzhafte paroxysmale Symptome wie die Trigeminusneuralgie oder schmerzhafte tonische Verkrampfungen der Extremitätenmuskulatur werden mit Carbamazepin als Mittel der ersten Wahl behandelt, Alternativen sind Lamotrigin, Gabapentin, Oxcarbazepin und andere Antikonvulsiva oder auch Misoprostol. Schmerzhafte „brennende” Missempfindungen bzw. Dysästhesien als häufigstes chronisches Schmerzsyndrom sprechen vor allem auf trizyklische Antidepressiva wie Amitriptylin an oder auf Carbamazepin. Alternativen sind Gabapentin und Lamotrigin. In der Eskalation kommen auch Opioide zum Einsatz, der Stellenwert der Cannabinoide ist derzeit noch nicht abschließend zu bewerten. 2. Schmerzen als indirekte Folge der MS: Schmerzhaft einschießende Spastik bessert sich oft unter adäquater Lagerung, medikamentös unter klassischen Antispastika wie Baclofen oder Tizanidin. Eine Alternative ist Gabapentin, in der Eskalation lokal Botulinumtoxin bzw. intrathekal Baclofen. Durch Fehlhaltung bedingte Gelenk- und Muskelschmerzen lassen sich durch Krankengymnastik und physikalische Therapie lindern, Druckläsionen durch optimal angepasste Hilfsmittel vermeiden. 3. Schmerzen durch therapeutische Maßnahmen kommen lokal vor allem bei subkutaner Injektion von β-Interferonen oder Glatiramerazetat vor und lassen sich durch optimale Technik bzw. lokale Kühlung positiv beeinflussen. Die systemischen Interferon-Nebenwirkungen wie Myalgien lassen sich durch Paracetamol oder Ibuprofen reduzieren. 4. Primär MS-unabhängige Schmerzen wie Rücken- oder Kopfschmerzen treten häufig auch bei MS-Betroffenen auf, können durch die Erkrankung jedoch beeinflusst werden. Die Therapie folgt den entsprechenden Leitlinien. Insgesamt wird nach genauer Analyse eines Schmerzes und seines Zusammenhangs mit der MS eine spezifische Therapie nach evidenzbasierten Kriterien möglich, die die Lebensqualität vieler Betroffener bessern hilft.

Abstract

While pain is a common problem in multiple sclerosis (MS) patients, it is frequently overlooked and has to be asked for actively. Pain can be classified into 4 diagnostically and therapeutically relevant categories. 1. pain directly related to MS: Painful paroxysmal symptoms like trigeminal neuralgia or painful tonic spasms are treated with carbamazepine as first choice, or lamotrigine, gabapentin, oxcarbazepine and other anticonvulsants. Painful “burning” dysaesthesias, the most frequent chronic pain syndrome, are treated with tricyclic antidepressants or carbamazepine, further options include gabapentin or lamotrigine. While escalation therapy may require opioids, the role of cannabinoids in the treatment of pain still has to be determined. 2. Pain indirectly related to MS: Pain related to spasticity often improves with adaequate physiotherapy. Drug treatment includes antispastic agents like baclofen or tizanidine, alternatively gabapentin. In severe cases botulinum toxin injections or intrathecal baclofen merit consideration. Physiotherapy and physical therapy may ameliorate malposition-induced joint and muscle pain. Moreover, painful pressure lesions should be avoided using optimally adjusted aids. 3. Treatment-related pain can occur with subcutaneous injections of beta interferons or glatiramer acetate and may be reduced by optimizing the injection technique and by local cooling. Systemic side effects of interferons like myalgias can be reduced by paracetamol or ibuprofen. 4. Pain unrelated to MS such as back pain or headache are frequent in MS patients and may be worsened by the disease. Treatment should be follow established guidelines. In summary, a careful analysis of the pain syndrome will allow the design of the appropriate treatment plan using various medical and non-medical options and thus will help to ameliorate the patients' quality of life.

Literatur

  • 1 Pöllmann W, Feneberg W. Schmerzen bei Multipler Sklerose - moderne Möglichkeiten der neurologischen Rehabilitation.  Nervenheilkunde. 1999;  18 526-531
    PubMedGoogle Scholar
  • 2 Fryze W, Zaborski J, Czlonkowska A. Pain in the course of multiple sclerosis.  Neurol Neurochir Pol. 2002;  36 275-284
    PubMedGoogle Scholar
  • 3 Ehde D M, Gibbons L E, Chwastiak L, Bombardier C H, Sullivan M D, Kraft G H. Chronic pain in a large community sample of persons with multiple sclerosis.  Mult Scler. 2003;  9 605-611
    CrossrefPubMedGoogle Scholar
  • 4 Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study.  Ital J Neurol Sci. 1995;  16 629-632
    PubMedGoogle Scholar
  • 5 Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis.  Acta Neurol Scand. 1991;  84 197-200
    PubMedGoogle Scholar
  • 6 Solomon P. Congruence between health professionals' and patients' pain ratings: a review of the literature.  Scand J Caring Sci. 2001;  15 174-180
    CrossrefPubMedGoogle Scholar
  • 7 Pöllmann W, Feneberg W, Erasmus L-P. Schmerzen bei Multipler Sklerose - ein immer noch unterschätztes Problem.  Nervenarzt. 2004;  75 135-140
    CrossrefPubMedGoogle Scholar
  • 8 Brichetto G, Messmer Uccelli M, Mancardi G L, Solaro C. Symptomatic medication use in multiple sclerosis.  Mult Scler. 2003;  9 458-460
    CrossrefPubMedGoogle Scholar
  • 9 Radbruch L, Loick G, Kiencke P, Lindena G, Sabatowski R, Grond S, Lehmann K A, Cleeland C S. Validation of the German version of the Brief Pain Inventory.  J Pain Symptom Manage.. 1999;  18 180-187
    CrossrefPubMedGoogle Scholar
  • 10 Stein C, Mendl G. The German counterpart to McGill pain questionnaire.  Pain. 1988;  32 251-255
    CrossrefPubMedGoogle Scholar
  • 11 Merskey H, Bogduk N. (eds) .Classification of chronic pain. 2nd ed. Seattle: IASP Press 1994
    Google Scholar
  • 12 Headache Classification Committee of the International Headache Society . The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24 (suppl. 1): 1 - 160. Kopfschmerzklassifikationskomitee der International Headache Society. Die internationale Klassifikation von Kopfschmerzerkrankungen. 2. Auflage.  Nervenheilkunde. 2003;  22 531-670
    PubMedGoogle Scholar
  • 13 Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review.  Health Technol Assess. 2003;  7 1-124
    PubMedGoogle Scholar
  • 14 Ferreira P H, Ferreira M L, Maher C G, Refshauge K, Herbert R D, Latimer J. Effect of applying different “levels of evidence” criteria on conclusions of Cochrane reviews of interventions for low back pain.  J Clin Epidemiol. 2002;  55 1126-1129
    CrossrefPubMedGoogle Scholar
  • 15 Lindena G, Diener H C, Hildebrandt J, Klinger R, Maier C, Schöps P, Tronnier V. Leitlinien zur Schmerztherapie. Methodische Qualität von Leitlinien zur Therapie von Patienten mit Schmerzen.  Schmerz. 2002;  16 194-204
    CrossrefPubMedGoogle Scholar
  • 16 Sindrup S H, Jensen T S. Effect of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.  Pain. 1999;  83 389-400
    CrossrefPubMedGoogle Scholar
  • 17 Sindrup S H, Jensen T S. Pharmacologic treatment of pain in polyneuropathy.  Neurology. 2000;  55 915-920
    PubMedGoogle Scholar
  • 18 Sindrup S H, Jensen T S. Pharmacotherapy of trigeminal neuralgia.  Clin J Pain. 2002;  18 22-27
    CrossrefPubMedGoogle Scholar
  • 19 Goodin D S, Frohman E M, Garmany G P, Halper J, Likosky W H, Lublin F D, Silberberg D H, Stuart W H, Noort S van den. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.  Neurology. 2002;  58 169-178
    CrossrefPubMedGoogle Scholar
  • 20 Young W F, Weaver M, Mishra B. Surgical outcome in patients with coexisting multiple sclerosis and spondylosis.  Acta Neurol Scand. 1999;  100 84-87
    PubMedGoogle Scholar
  • 21 Bashir K, Cai C Y, Moore T A, Whitaker J N, Hadley M N. Surgery for cervical spinal cord compression in patients with multiple sclerosis.  Neurosurgery. 2000;  47 637-642
    PubMedGoogle Scholar
  • 22 Etus V, Akansel G, Ilbay K, Koc K, Ceylan S. Multiple sclerosis and coexisting intradural extramedullary spinal cord tumor: a case report.  Neurol Sci. 2002;  23 119-122
    CrossrefPubMedGoogle Scholar
  • 23 Optic Neuritis Study Group . The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial.  Arch Ophthalmol. 1991;  109 1673-1678
    CrossrefPubMedGoogle Scholar
  • 24 Haas D C, Kent P F, Friedman D I. Headache caused by single lesion of multiple sclerosis in the periaqueductal gray area.  Headache. 1993;  33 452-455
    CrossrefPubMedGoogle Scholar
  • 25 Feneberg W, Pöllmann W. Headache in multiple sclerosis - a prospective study using the IHS classification criteria.  J Neurol. 2000;  247, suppl 3 III/179-(Abstract)
    PubMedGoogle Scholar
  • 26 MS-Therapie Konsensusgruppe MSTKG . Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung.  Nervenarzt. 2002;  73 556-563
    CrossrefPubMedGoogle Scholar
  • 27 Soyka D. Trigeminusneuralgie und Multiple Sklerose.  Nervenheilkunde. 1999;  18 522-525
    PubMedGoogle Scholar
  • 28 Diener H C. Kommission „Leitlinien” der Deutschen Gesellschaft für Neurologie .Leitlinien für Diagnostik und Therapie in der Neurologie. 2. Auflage. Stuttgart: Thieme 2003 Postpunktionelles Syndrom 325-327 Migräne 328-334 Episodischer und chronischer Spannungskopfschmerz 337 - 340 Trigeminusneuralgie 341 - 346 Spastik 388-393
    Google Scholar
  • 29 DGN Deutsche Gesellschaft für Neurologie .Leitlinien 2003. www.dgn.org
    Google Scholar
  • 30 Wiffen P, Collins S D, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain.  Cochrane Database Syst Rev. 2000;  3 CD001133
    PubMedGoogle Scholar
  • 31 Hooge J P, Redekop W K. Trigeminal neuralgia in multiple sclerosis.  Neurology. 1995;  45 1294-1296
    CrossrefPubMedGoogle Scholar
  • 32 Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine.  BMJ. 2000;  320 1113
    CrossrefPubMedGoogle Scholar
  • 33 Leandri M, Lundardi G, Inglese M, Messmer-Uccelli M, Mancardi G L, Gottlieb A. et al . Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis.  J Neurol. 2000;  247 556-558
    PubMedGoogle Scholar
  • 34 Zakrzewska J M, Patsalos P N. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia.  J Neurol Neurosurg Psychiatry. 1989;  52 472-476
    PubMedGoogle Scholar
  • 35 Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain.  J Pain Symptom Manage. 2003;  25 (5 Suppl) S31-S35
    CrossrefPubMedGoogle Scholar
  • 36 Schmidt D, Elger C E. Worin unterscheidet sich Oxcarbazepin von Carbamazepin?.  Nervenarzt. 2004;  75 153-160
    CrossrefPubMedGoogle Scholar
  • 37 Backonja M M. Use of anticonvulsants for treatment of neuropathic pain.  Neurology. 2002;  59 suppl. 2 S14-S17
    PubMedGoogle Scholar
  • 38 Solaro C, Lunardi G L, Capello E, Inglese M, Messmer Uccelli M, Uccelli A. et al . An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.  Neurology. 1998;  51 609-611
    PubMedGoogle Scholar
  • 39 Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi G L. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis.  Eur Neurol. 2000;  44 45-48
    CrossrefPubMedGoogle Scholar
  • 40 Khan O A. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients.  Neurology. 1998;  51 611-614
    PubMedGoogle Scholar
  • 41 Zakrzewska J M, Chaudhry Z, Nurmikko T J, Patton D W, Mullens E L. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial.  Pain. 1997;  73 223-230
    CrossrefPubMedGoogle Scholar
  • 42 Lunardi G, Leandri M, Albano C, Cultrera S, Fracassi M, Rubino V. et al . Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia.  Neurology. 1997;  48 1714-1717
    PubMedGoogle Scholar
  • 43 Lüttmann R J, Brinkmann B, Loddenkemper T, Frese A, Bethke F, Husstedt I W, Evers S. Misoprostol in the treatment of trigeminal neuralgia in MS patients: a report of three cases.  Cephalalgia. 2000;  20 382
    PubMedGoogle Scholar
  • 44 Reder A T, Arnason B G. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue.  Neurology. 1995;  45 1097-1100
    PubMedGoogle Scholar
  • 45 DMKG Study Group . Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis.  J Neurol. 2003;  250 542-545
    PubMedGoogle Scholar
  • 46 Fromm G H, Terrence C F, Chattha A S. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up.  Ann Neurol. 1984;  15 240-244
    CrossrefPubMedGoogle Scholar
  • 47 Parmar B S, Shah K H, Gandhi I C. Baclofen in trigeminal neuralgia - a clinical trial.  Indian J Dent Res. 1989;  1 109-113
    PubMedGoogle Scholar
  • 48 Steardo L, Leo A, Marano E. Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial.  Eur Neurol. 1984;  23 51-55
    PubMedGoogle Scholar
  • 49 Zvartau-Hind M, Din M U, Gilani A, Lisak R P, Khan O A. Topiramate relieves refractory trigeminal neuralgia in MS patients.  Neurology. 2000;  55 1587-1588
    PubMedGoogle Scholar
  • 50 Solaro C, Uccelli M M, Brichetto G, Gaspperini C, Mancardi G. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia.  J Pain Symptom Manage. 2001;  21 367-368
    CrossrefPubMedGoogle Scholar
  • 51 Gilron I, Booher S L, Rowan J S, Max M B. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study.  Clin Neuropharmacol. 2001;  24 109-112
    PubMedGoogle Scholar
  • 52 D'Aleo G, Sessa E, di Bella P, Rifici C, Restivo D A, Bramanti P. Topiramate modulation of R3 nociceptive reflex in multiple sclerosis patients suffering paroxysmal symptoms.  J Neurol. 2001;  248 996-999
    PubMedGoogle Scholar
  • 53 Chandra B. The use of clonazepam in the treatment of tic douloureux (a preliminary report).  Proc Aust Assoc Neurol. 1976;  13 119-122
    PubMedGoogle Scholar
  • 54 Fusco B M, Alessandri M. Analgesic effect of capsaicin in idiopathic trigeminal neuralgia.  Anesth Analg. 1992;  74 375-377
    PubMedGoogle Scholar
  • 55 Lechin F, Dijs B van der, Lechin M E, Amat J, Lechin A E, Cabrera A. et al . Pimozide therapy for trigeminal neuralgia.  Arch Neurol. 1989;  46 960-963
    CrossrefPubMedGoogle Scholar
  • 56 Peiris J B, Perera G L, Devendra S V, Lionel N D. Sodium valproate in trigeminal neuralgia.  Med J Aust. 1980;  2 278
    PubMedGoogle Scholar
  • 57 Paulus W, Evers S, May A, Steude U, Wolowski A, Pfaffenrath V. DMKG .Therapie und Prophylaxe von Gesichtsneuralgien und anderen Formen der Gesichtsschmerzen. Überarbeitete Therapieempfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft. Schmerz 2003 Jan; 17 (1): 74-91 www.dmkg.de
    Google Scholar
  • 58 Berk C, Constantoyannis C, Honey C R. The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy.  Can J Neurol Sci. 2003;  30 220-223
    PubMedGoogle Scholar
  • 59 Kondziolka D, Lunsford L D, Bissonette D J. Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia.  Can J Neurol Sci. 1994;  21 137-140
    PubMedGoogle Scholar
  • 60 Broggi G, Ferroli P, Franzini A, Pluderi M, La Mantia L, Milanese C. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis.  Lancet. 1999;  354 1878-1879
    CrossrefPubMedGoogle Scholar
  • 61 Broggi G, Ferroli P, Franzini A, Servello D, Dones I. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis.  J Neurol Neurosurg Psychiatry. 2000;  68 59-64
    CrossrefPubMedGoogle Scholar
  • 62 Kondziolka D, Lunsford L, Flickinger J. Stereotactic radiosurgery for the treatment of trigeminal neuralgia.  Clin J Pain. 2002;  18 42-47
    CrossrefPubMedGoogle Scholar
  • 63 Huang E, Teh B S, Zeck O, Woo S Y, Lu H H, Chiu J K, Butler E B, Gormley W B, Carpenter L S. Gamma knife radiosurgery for treatment of trigeminal neuralgia in multiple sclerosis patients.  Stereotact Funct Neurosurg. 2002;  79 (1) 44-50
    PubMedGoogle Scholar
  • 64 Minagar A, Sheremata W A. Glossopharyngeal neuralgia and MS.  Neurology. 2000;  54 1368-1370
    CrossrefPubMedGoogle Scholar
  • 65 Garcia-Callejo F J, Velert-Vila M M, Talamantes-Escriba F, Blay-Galaud L. Clinical response of gabapentin for glossopharyngeal neuralgia.  Rev Neurol. 1999;  28 (4) 380-384
    PubMedGoogle Scholar
  • 66 Espir M L, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol).  J Neurol Neurosurg Psychiatry. 1970;  33 528-531
    PubMedGoogle Scholar
  • 67 Twomey J A, Espir M LE. Paroxysmal symptoms as the first manifestations of multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1980;  43 296-304
    PubMedGoogle Scholar
  • 68 Cianchetti C, Zuddas A, Randazzo A P, Perra L, Marossu M G. Lamotrigine adjunctive therapy in painful phenomena in MS: Preliminary observations.  Neurology. 1999;  53 433
    PubMedGoogle Scholar
  • 69 Voiculescu V, Pruskauer-Apostol B, Alecu C. Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1975;  38 191-193
    PubMedGoogle Scholar
  • 70 Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias.  Mov Disord. 2002;  17 726-734
    CrossrefPubMedGoogle Scholar
  • 71 Shibasaki H, Kuroiwa Y. Painful tonic seizures in multiple sclerosis.  Arch Neurol. 1974;  30 47-51
    PubMedGoogle Scholar
  • 72 Spissu A, Cannas A, Ferrigno P, Pelaghi A E, Spissu M. Anatomic correlates of painful tonic spasms in multiple sclerosis.  Mov Disord. 1999;  14 331-335
    CrossrefPubMedGoogle Scholar
  • 73 Libenson M H, Stafstrom C E, Rosman N P. Tonic “seizures” in a patient with brainstem demyelination. A MRI study of brain and spinal cord.  Pediatr Neurol. 1994;  11 258-262
    CrossrefPubMedGoogle Scholar
  • 74 Kuroiwa Y, Shibasaki H. Painful tonic seizure in multiple sclerosis. Treatment with diphenylhydantoin and carbamazepine.  Folia Pychiatr Neurol Jap. 1968;  22 107-119
    PubMedGoogle Scholar
  • 75 Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine.  J Neurol Sci. 1999;  162 162-168
    CrossrefPubMedGoogle Scholar
  • 76 Okada S, Kinoshita M, Fujioka T, Yoshimura M. Two cases of multiple sclerosis with painful tonic seizures and dysesthesia ameliorated by the administration of mexiletine.  Jpn J Med. 1991;  30 373-375
    PubMedGoogle Scholar
  • 77 Galer B S, Harle J, Rowbotham M C. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study.  J Pain Symptom Manage. 1996;  12 161-167
    CrossrefPubMedGoogle Scholar
  • 78 Sethi K D, Hess D C, Huffnagle V H, Adams R J. Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease.  Neurology. 1992;  42 919-921
    PubMedGoogle Scholar
  • 79 Vermote R, Ketelaer P, Carton H. Pain in multiple sclerosis patients.  Clin Neurol Neurosurg. 1986;  88 87-92
    PubMedGoogle Scholar
  • 80 Brochet B, Michel P, Henry P. Pain complaints in outpatients with multiple sclerosis: description and consequences on disability.  Pain Clinic. 1992;  5 157-164
    PubMedGoogle Scholar
  • 81 Clifford D B, Trotter J L. Pain in multiple sclerosis.  Arch Neurol. 1984;  41 1270-1272
    CrossrefPubMedGoogle Scholar
  • 82 Moulin D E, Foley K M, Ebers G C. Pain syndromes in multiple sclerosis.  Neurology. 1988;  38 1830-1834
    CrossrefPubMedGoogle Scholar
  • 83 Feneberg W, Meister H, Pöllmann W. Sensibilitätsstörungen und Schmerzen. Kapitel 8. In: Wötzel C, Wehner C, Pöllmann W, König N (Hrsg.). Therapie der Multiplen Sklerose. Ein interdisziplinäres Behandlungskonzept. 2. Auflage München: Pflaum 2000: 132-138
    Google Scholar
  • 84 Zenz M, Jurna I. eds .Lehrbuch der Schmerztherapie. Stuttgart: Wissenschaftliche Verlagsanstalt 2001: 970
    Google Scholar
  • 85 Zenz M, Strumpf M, Willweber-Strumpf A. Taschenbuch der Schmerztherapie. 2. Auflage. Stuttgart: Wissenschaftliche Verlagsanstalt 2004: 262
    Google Scholar
  • 86 Backonja M. Anticonvulsants for the treatment of neuropathic pain syndromes.  Curr Pain Headache Rep. 2003;  7 (1) 39-42
    PubMedGoogle Scholar
  • 87 Finnerup N B, Gottrup H, Jensen T S. Anticonvulsants in central pain.  Expert Opin Pharmacother. 2002;  3 1411-1420
    CrossrefPubMedGoogle Scholar
  • 88 Dworkin R H, Backonja M, Rowbotham M C, Allen R R, Argoff C R, Bennett G J, Bushnell M C, Farrar J T, Galer B S, Haythornthwaite J A, Hewitt D J, Loeser J D, Max M B, Saltarelli M, Schmader K E, Stein C, Thompson D, Turk D C, Wallace M S, Watkins L R, Weinstein S M. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.  Arch Neurol. 2003;  60 (11) 1524-1534
    CrossrefPubMedGoogle Scholar
  • 89 Houtchens M K, Richert J R, Sami A, Rose J W. Open label gabapentin treatment for pain in multiple sclerosis.  Mult Scler. 1997;  3 250-253
    PubMedGoogle Scholar
  • 90 Samkoff L M, Daras M, Tuchman A J, Koppel B S. Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.  Neurology. 1997;  49 304-305
    PubMedGoogle Scholar
  • 91 Vestergaard K, Andersen G, Gottrup H, Kristensen B T, Jensen T S. Lamotrigine for central poststroke pain: a randomized controlled trial.  Neurology. 2001;  56 184-190
    PubMedGoogle Scholar
  • 92 Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study.  Neurology. 2001;  57 (3) 505-509
    CrossrefPubMedGoogle Scholar
  • 93 McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis.  Clin J Pain. 1998;  14 269-270
    CrossrefPubMedGoogle Scholar
  • 94 Sabatowski R, Galvez R, Cherry D A, Jacquot F, Vincent E, Maisonobe P, Versavel M. The 1008 - 045 Study Group . Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.  Pain. 2004;  109 (1 - 2) 26-35
    CrossrefPubMedGoogle Scholar
  • 95 Dworkin R H, Corbin A E, Young Jr J P, Sharma U, LaMoreaux L, Bockbrader H, Garofalo E A, Poole R M. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.  Neurology. 2003;  60 (8) 1274-1283
    PubMedGoogle Scholar
  • 96 Wallin J, Cui J G, Yakhnitsa V, Schechtmann G, Meyerson B A, Linderoth B. Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy.  Eur J Pain. 2002;  6 (4) 261-272
    CrossrefPubMedGoogle Scholar
  • 97 Mason L, Moore R A, Derry S, Edwards J E, McQuay H J. Systematic review of topical capsaicin for the treatment of chronic pain.  BMJ. 2004;  328 991-994
    CrossrefPubMedGoogle Scholar
  • 98 Davies P S, Galer B S. Review of lidocaine patch 5 % studies in the treatment of postherpetic neuralgia.  Drugs. 2004;  64 (9) 937-947
    PubMedGoogle Scholar
  • 99 Baron R. Arzneimittel zur Behandlung neuropathischer Schmerzen. In: Fox JM, Jörg J (eds). Neurologische Pharmakotherapie Stuttgart: Thieme 2004: 453-464
    Google Scholar
  • 100 Kalman S, Osterberg A, Sorensen J, Boivie J, Bertler A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i. v. morphine.  Eur J Pain. 2002;  6 69-80
    CrossrefPubMedGoogle Scholar
  • 101 Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain.  Neurology. 2002;  58 554-563
    PubMedGoogle Scholar
  • 102 Raja S N, Haythornthwaite J A, Pappagallo M, Clark M R, Travison T G, Sabeen S, Royall R M, Max M B. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial.  Neurology. 2002;  59 1015-1021
    PubMedGoogle Scholar
  • 103 Mattia C, Paoletti F, Coluzzi F, Boanelli A. New antidepressants in the treatment of neuropathic pain. A review.  Minerva Anestesiol. 2002;  68 (3) 105-114
    PubMedGoogle Scholar
  • 104 Sindrup S H, Bach F W, Madsen C, Gram L F, Jensen T S. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.  Neurology. 2003;  60 1284-1289
    PubMedGoogle Scholar
  • 105 Schüler P, Seibel K, Chevts V, Schaffler K. Analgetische Wirkung des selektiven Noradrenalin-Wiederaufnahme-Hemmers Reboxetin.  Nervenarzt. 2002;  73 (2) 149-154
    CrossrefPubMedGoogle Scholar
  • 106 Wade D T, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.  Clin Rehabil. 2003;  17 21-29
    CrossrefPubMedGoogle Scholar
  • 107 Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. UK MS Research Group . Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.  Lancet. 2003;  362 (9395) 1517-1526
    CrossrefPubMedGoogle Scholar
  • 108 Hocking G, Cousins M J. Ketamine in chronic pain management: an evidence-based review.  Anesth Analg. 2003;  97 1730-1739
    CrossrefPubMedGoogle Scholar
  • 109 Sjölund B H. Pain and rehabilitation after spinal cord injury: the case of sensory spasticity?.  Brain Res Brain Res Rev. 2002;  40 (1 - 3) 250-256
    CrossrefPubMedGoogle Scholar
  • 110 Eide P K, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo.  Pain. 1994;  58 (3) 347-354
    CrossrefPubMedGoogle Scholar
  • 111 Chiba S, Ito M, Matsumoto H. Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis.  Can J Neurol Sci. 1992;  19 309
    PubMedGoogle Scholar
  • 112 Otto M, Bach F W, Jensen T S, Sindrup S H. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial.  Neurology. 2004;  62 285-288
    PubMedGoogle Scholar
  • 113 Herman R M, D'Luzansky S C, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study.  Clin J Pain. 1992;  8 338-345
    PubMedGoogle Scholar
  • 114 Becker R, Uhle E I, Alberti O, Bertalanffy H. Continuous intrathecal baclofen infusion in the management of central deafferentation pain.  J Pain Symptom Manage. 2000;  20 313-315
    CrossrefPubMedGoogle Scholar
  • 115 Paice J A, Penn R D, Kroin J S. Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases.  Neurosurgery. 1996;  38 203-207
    PubMedGoogle Scholar
  • 116 Harke H, Rosenow E, Tronnier V, Fromme C, Deynet G, Gretenkort P, Buschmann D, Rohr P, Ladleif H U, Glinski E von, Schutze G, Schultze R, Keller H L, Kniesel B, Pfeifer R, Lux E. Standardisierung invasiver neuromodulativer Verfahren.  Schmerz. 2003;  17(1) 44-49
    CrossrefPubMedGoogle Scholar
  • 117 Nix W A. Was ist gesichert in der Schmerztherapie? Haben Neuroleptika eine analgetische Potenz? Eine Metaanalyse.  Schmerz. 1998;  12 30-38
    CrossrefPubMedGoogle Scholar
  • 118 Jurna I, Motsch J. Nichtanalgetika: Antidepressiva, Antikonvulsiva, Neuroleptika, Tranquillantien und zentrale Muskelrelaxantien, Clonidin, Cortison. Kapitel 3. In: Zenz M, Jurna I. Lehrbuch der Schmerztherapie Stuttgart: Wissenschaftliche Verlagsanstalt 2001: 281-293
    Google Scholar
  • 119 Graff-Radford S B, Shaw L R, Naliboff B N. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia.  Clin J Pain. 2000;  16 188-192
    PubMedGoogle Scholar
  • 120 Ehde D M, Jensen M P, Engel J M, Turner J A, Hoffmann A J, Carden D D. Chronic pain secondary to disability: a review.  Clin J Pain. 2003;  19 3-17
    CrossrefPubMedGoogle Scholar
  • 121 Schayck R H van, Weiller C. Behandlung akuter und chronischer Schmerzen in der neurologischen Rehabilitation (Teil I).  Neurol Rehabil. 2002;  8 1-17
    PubMedGoogle Scholar
  • 122 Pöllmann W, Albrecht H, Wötzel C, König N H. Physiotherapie bei Multipler Sklerose. In: Zettl UK, Mix E (Hrsg.). Multiple Sklerose. Kausalorientierte, symptomatische und rehabilitative Therapie Berlin: Springer 2001: 293-305
    Google Scholar
  • 123 Klewer J, Pöhlau D, Nippert I, Haas J, Kugler J. Problems reported by elderly patients with multiple sclerosis.  J Neurosci Nurs. 2001;  33 167-171
    PubMedGoogle Scholar
  • 124 Wötzel C, Wehner C, Pöllmann W, König N. Therapie der Multiplen Sklerose. Ein interdisziplinäres Behandlungskonzept. 2. Auflage. München: Pflaum 2000
    Google Scholar
  • 125 Sachais B A, Logue J N, Carey M S. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis.  Arch Neurol. 1977;  34 422-428
    PubMedGoogle Scholar
  • 126 Ward A B, Kadies M. The management of pain in spasticity.  Disabil Rehabil. 2002;  24 443-453
    CrossrefPubMedGoogle Scholar
  • 127 Shakespeare D, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis.  Cochrane Database Syst Rev. 2003;  4 CD001332
    PubMedGoogle Scholar
  • 128 Mueller M E, Gruenthal M, Olson W L, Olson W H. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.  Arch Phys Med Rehabil. 1997;  78 521-524
    CrossrefPubMedGoogle Scholar
  • 129 Solaro C, Uccelli M M, Guglieri P, Uccelli A, Mancardi G L. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.  Mult Scler. 2000;  6 192-193
    CrossrefPubMedGoogle Scholar
  • 130 Cutter N C, Scott D D, Johnson J C, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomised trial.  Arch Phys Med Rehabil. 2000;  81 164-169
    CrossrefPubMedGoogle Scholar
  • 131 Schapiro R T. Management of spasticity, pain, and paroysmal phenomena in multiple sclerosis.  Curr Neurol Neurosci Reports. 2001;  1 299-302
    PubMedGoogle Scholar
  • 132 Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis.  Arch Neurol. 2003;  60 1772-1774
    CrossrefPubMedGoogle Scholar
  • 133 Lang A M. Botulinum toxin type A therapy in chronic pain disorders.  Arch Phys Med Rehabil. 2003;  84 (3 Suppl 1) S69-73
    CrossrefPubMedGoogle Scholar
  • 134 Göbel H, Jost W H. Botulinum toxin in specific pain therapy.  Schmerz. 2003;  17 149-165
    CrossrefPubMedGoogle Scholar
  • 135 Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W. Management of spasticity associated pain with botulinum toxin A.  J Pain Symptom Manage. 2000;  20 44-49
    CrossrefPubMedGoogle Scholar
  • 136 Chalkiadaki A, Rohr U P, Hefter H. Frühe Schmerzreduktion in der Therapie von Spastik nach einmaliger Botulinustoxin-A-Injektion.  Dtsch Med Wochenschr. 2001;  126 1361-1364
    Article in Thieme ConnectPubMedGoogle Scholar
  • 137 Dario A, Scamoni C, Bono G, Ghezzi A, Zaffaroni M. Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion.  Funct Neurol. 2001;  16 311-315
    PubMedGoogle Scholar
  • 138 Middel B, Kuipers-Upmeijer H, Bouma J, Staal M. et al . Effect of intrathecal baclofen delivered by an implanted programmable pump on health-related quality of life in patients with severe spasticity.  J Neurol Neurosurg Psychiatry. 1997;  63 204-209
    PubMedGoogle Scholar
  • 139 Ochs A, Tonn J C. Functional outcome and clinical significance of long-term intrathecal baclofen therapy for severe spasticity.  J Neuro Rehab. 1996;  10 159-166
    PubMedGoogle Scholar
  • 140 Dahm P O, Nitescu P V, Appelgren L K, Curelaru I I. Long-term intrathecal (i. t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis.  Eur J Pain. 1998;  2 81-85
    CrossrefPubMedGoogle Scholar
  • 141 Jarrett L, Nandi P, Thompson A J. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?.  J Neurol Neurosurg Psychiatry. 2002;  73 705-709
    CrossrefPubMedGoogle Scholar
  • 142 Heun R, Emser W, Schimrigk K. Evozierte Potenziale unter intrathekaler und systemischer Kortikosteroid-Therapie bei Multipler Sklerose.  Z EEG-EMG. 1987;  20 88-91
    PubMedGoogle Scholar
  • 143 Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Muller T. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.  J Neurol Sci. 2003;  211 81-84
    PubMedGoogle Scholar
  • 144 Salame K, Ouaknine G E, Rochkind S, Constantini S, Razon N. Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience.  Isr Med Assoc J. 2003;  5 (8) 543-546
    PubMedGoogle Scholar
  • 145 Philadelphia Panel . Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for neck pain.  Phys Ther. 2001;  81 1701-1717
    PubMedGoogle Scholar
  • 146 Philadelphia Panel . Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain.  Phys Ther. 2001;  81 1719-1730
    PubMedGoogle Scholar
  • 147 Philadelphia Panel . Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for knee pain.  Phys Ther. 2001;  81 1675-1700
    PubMedGoogle Scholar
  • 148 Feine J S, Lund J P. An assessment of the efficacy of physical therapy and physical modalities for the control of chronic musculoskeletal pain.  Pain. 1997;  71 5-23
    CrossrefPubMedGoogle Scholar
  • 149 Korthals de Bos I B, Hoving J L, Tulder M W van, Rutten van Molken M P, Ader H J, de Vet H C, Koes B W, Vondeling H, Bouter L M. Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial.  BMJ. 2003;  326 911
    CrossrefPubMedGoogle Scholar
  • 150 Price C I. Shoulder pain after stroke: a research challenge.  Age Ageing. 2002;  31 Suppl 3 36-38
    CrossrefPubMedGoogle Scholar
  • 151 Turner-Stokes L, Jackson D. Shoulder pain after stroke: a review of the evidence base to inform the development of an integrated care pathway.  Clin Rehabil. 2002;  16 276-298
    CrossrefPubMedGoogle Scholar
  • 152 Arzneimittelkommision der deutschen Ärzteschaft .Degenerative Gelenkerkrankungen. Therapieempfehlungen der AKDAE, 2. Auflage. 2001 www.akdae.de
    Google Scholar
  • 153 Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group.  BMJ. 1998;  317 526-530
    CrossrefPubMedGoogle Scholar
  • 154 Schnitzer T J. American College of Rheumatology . Update of ACR guidelines for osteoarthritis: role of the coxibs.  J Pain Symptom Manage. 2002;  23 (4 Suppl) S24-30
    CrossrefPubMedGoogle Scholar
  • 155 Towheed T E, Judd M J, Hochberg M C, Wells G. Acetaminophen for osteoarthritis.  Cochrane Database Syst Rev. 2003;  (2) CD004257
    PubMedGoogle Scholar
  • 156 Roth S H. A new role for opioids in the treatment of arthritis.  Drugs. 2002;  62 255-263
    PubMedGoogle Scholar
  • 157 Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm.  Curr Pain Headache Rep. 2002;  6 460-469
    PubMedGoogle Scholar
  • 158 American Geriatrics Society . Exercise prescription for older adults with osteoarthritis pain: Consensus practice recommendations.  J Am Geriatr Soc. 2001;  49 808-823
    CrossrefPubMedGoogle Scholar
  • 159 Albrecht H, Pöllmann W, König N. Akute Fußheberparese bei multipler Sklerose.  Nervenarzt. 1996;  67 163-169
    PubMedGoogle Scholar
  • 160 Feneberg W. Blasenstörungen bei Multipler Sklerose. MSTKG-Konsensusgruppe Symptomatische Therapie 2004
    Google Scholar
  • 161 Neilley L K, Goodin D S, Goodkin D E, Hauser S L. Side effect profile of interferon beta-1b in MS: results of an open label trial.  Neurology. 1996;  46 552-554
    CrossrefPubMedGoogle Scholar
  • 162 Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy.  Multiple Sclerosis. 2002;  8 15-18
    CrossrefPubMedGoogle Scholar
  • 163 Walther E U, Dang T, Hohlfeld R. Management of side-effects of beta-interferon therapy in MS.  Int MSJ. 1999;  5 65-70
    PubMedGoogle Scholar
  • 164 Pöllmann W, Erasmus L-P, Feneberg W, Then Bergh F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.  Neurology. 2002;  59 636-639
    PubMedGoogle Scholar
  • 165 Dalakas M C. Intravenous immune globulin therapy for neurologic diseases.  Ann Intern Med. 1997;  126 721-730
    CrossrefPubMedGoogle Scholar
  • 166 Finkel A G, Howard J F, Mann J D. Successful treatment of headache related to intravenous immunglobulin with antimigraine medication.  Headache. 1998;  38 317-321
    CrossrefPubMedGoogle Scholar
  • 167 Evans R W, Armon C, Frohman E M, Goodin D S. Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology.  Neurology. 2000;  55 909-914
    CrossrefPubMedGoogle Scholar
  • 168 Samanta J, Kendall J, Samanta A. 10-minute consultation: chronic low back pain.  BMJ. 2003;  326 535
    CrossrefPubMedGoogle Scholar
  • 169 Philadelphia Panel . Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain.  Phys Ther. 2001;  81 1641-1674
    PubMedGoogle Scholar
  • 170 Tulder M W van, Malmivaara A, Esmail R, Koes B W. Exercise therapy for low back pain (Cochrane Methodology Review). In: The Cochrane Library, Issue 4. 2003 Chichester, UK: John Wiley & Sons, Ltd.
    Google Scholar
  • 171 Furlan A D, Brosseau L, Imamura M, Irvin E. Massage for low back pain.  Cochrane Database Syst Rev.. 2002;  (2) CD001929
    PubMedGoogle Scholar
  • 172 Gadsby J G, Flowerdew M W. Transcutaneous electrical nerve stimulation and acupuncture-like transcutaneous electrical nerve stimulation for chronic low back pain.  Cochrane Database Syst Rev. 2000;  (2) CD000210
    PubMedGoogle Scholar
  • 173 Milne S, Welch V, Brosseau L, Saginur M, Shea B, Tugwell P, Wells G. Transcutaneous electrical nerve stimulation (TENS) for chronic low back pain.  Cochrane Database Syst Rev. 2001;  (2) CD003008
    PubMedGoogle Scholar
  • 174 Brosseau L, Milne S, Robinson V, Marchand S, Shea B, Wells G, Tugwell P. Efficacy of the transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a meta-analysis.  Spine. 2002;  27 596-603
    CrossrefPubMedGoogle Scholar
  • 175 Al-Smadi J, Warke K, Wilson I, Cramp A F, Noble G, Walsh D M, Lowe-Strong A S. A pilot investigation of the hypoalgesic effects of transcutaneous electrical nerve stimulation upon low back pain in people with multiple sclerosis.  Clin Rehabil. 2003;  17 742-749
    CrossrefPubMedGoogle Scholar
  • 176 Leibing E, Leonhardt U, Koster G, Goerlitz A, Rosenfeldt J A, Hilgers R, Ramadori G. Acupuncture treatment of chronic low-back pain - a randomized, blinded, placebo-controlled trial with 9-month follow-up.  Pain. 2002;  96 189-196
    CrossrefPubMedGoogle Scholar
  • 177 Arzneimittelkommission der deutschen Ärzteschaft .Kreuzschmerzen. Therapieempfehlungen der AKDAE, 2. Auflage. 2000 www.akdae.de
    Google Scholar
  • 178 Tulder M W van, Scholten R JPM, Koes B W, Deyo R A. Non-steroidal anti-inflammatory drugs for low back pain (Cochrane Methodology Review). In: The Cochrane Library, Issue 4. 2003 Chichester, UK: John Wiley & Sons, Ltd.
    Google Scholar
  • 179 Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. A randomised, double-blind study.  Neurology. 2001;  56 1290-1293
    CrossrefPubMedGoogle Scholar
  • 180 Ramirez-Lassepas M, Tulloch J W, Quinones M R, Snyder B D. Acute radicular pain as a presenting symptom in multiple sclerosis.  Arch Neurol. 1992;  49 255-258
    PubMedGoogle Scholar
  • 181 Portenoy R K, Yang K, Thorton D. Chronic intractable pain: an atypical presentation of multiple sclerosis.  J Neurol. 1988;  235 226-228
    PubMedGoogle Scholar
  • 182 Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporitic vertebral fractures.  Clin Rheumatol. 1999;  18 266-267
    CrossrefPubMedGoogle Scholar
  • 183 Goemaere S, Laere M van, De Neve P, Kaufman J M. Bone mineral status in paraplegic patients who do or do not perform standing.  Osteoporos Int. 1994;  4 138-143
    CrossrefPubMedGoogle Scholar
  • 184 Göbel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society.  Cephalalgia. 1994;  14 97-106
    CrossrefPubMedGoogle Scholar
  • 185 Headache Classification Committee of the International Headache Society . Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.  Cephalalgia. 1988;  8, suppl. 7 1-96 Klassifikation und diagnostische Kriterien für Kopfschmerzerkrankungen, Kopfneuralgien und Gesichtsschmerz.  Nervenheilkunde. 1989;  8 161-203
    CrossrefPubMedGoogle Scholar
  • 186 Rasmussen B K. Epidemiology of headache.  Cephalalgia. 1995;  15 45-68
    PubMedGoogle Scholar
  • 187 Lampl C, Buzath A, Baumhackl U, Klingler D. One-year prevalence of migraine in Austria: a nation-wide survey.  Cephalalgia. 2003;  23 280-286
    CrossrefPubMedGoogle Scholar
  • 188 Freedman M S, Gray T A. Vascular headache: a presenting symptom of multiple sclerosis.  Can J Neurol Sci. 1989;  16 63-66
    PubMedGoogle Scholar
  • 189 Frese A, Friedrich H, Poehlau D, Schimrigk S, Bethke F, Lüttmann R J, Husstedt I W, Evers S. The prevalence of migraine in multiple sclerosis patients.  Cephalalgia. 2001;  21 317-317 (abstract)
    PubMedGoogle Scholar
  • 190 Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck R V, Coenen H H, Diener H C. Brain stem activation in spontaneous human migraine attacks.  Nature Med. 1995;  1 (7) 658-660
    PubMedGoogle Scholar
  • 191 Deutsche Migräne und Kopfschmerzgesellschaft .www.dmkg.de

Dr. Walter Pöllmann

Marianne Strauß-Klinik

Milchberg 21

82335 Berg ·

Email: walter.poellmann@ms-klinik.info